한빛사논문
- 조회199
Jae-Hyeon Lee 1,2,7, Hansol Lim 2,7, Gaeun Ma 2, Seho Kweon 3,4,*, Seong Jin Park 5, Minho Seo 1,2, Jun-Hyuck Lee 2, Seong-Bin Yang 2, Han-Gil Jeong 6 & Jooho Park 1,2,*
1Department of Biomedical Chemistry, College of Biomedical and Health Science, Konkuk University, Seoul, Republic of Korea.
2Department of Applied Life Science, BK21 Program, Konkuk University, Chungju, Republic of Korea.
3Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
4College of Pharmacy, Chonnam National University, Gwangju, Republic of Korea.
5College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
6Division of Neurocritical Care, Department of Neurosurgery and Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Republic of Korea.
7These authors contributed equally: Jae-Hyeon Lee, Hansol Lim.
*Corresponding authors: correspondence to Seho Kweon or Jooho Park
Abstract
Low-molecular-weight heparin (LMWH), derived from unfractionated heparin (UFH), has enhanced anticoagulant efficacy, long duration of action, and extended half-life. Patients receiving LMWH for preventive therapies would strongly benefit from its long-term effects, however, achieving this is challenging. Here, we design and evaluate a nanoengineered LMWH and octadecylamine conjugate (LMHO) that can act for a long time while maintaining close to 97 ± 3% of LMWH activity via end-specific conjugation of the reducing end of LMWH. LMHO can self-assemble into nanoparticles with an average size of 105 ± 1.7 nm in water without any nanocarrier and can be combined with serum albumin, resulting in a lipid-based albumin shuttling effect. Such molecules can circulate in the bloodstream for 4–5 days. We corroborate the self-assembly capability of LMHO and its interaction with albumin through molecular dynamics (MD) simulations and transmission electron microscopy (TEM) analysis. This innovative approach to carrier-free polysaccharide delivery, enhanced by nanoengineered albumin shuttling, represents a promising platform to address limitations in conventional therapies.
논문정보
- Research article
- 2024년 08월 (BRIC 등록일 2024-08-09)
- 국내 연구진
- 의약학 > 약학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기
